bisoprolol has been researched along with Obesity in 4 studies
Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetic data for the three drugs were qualitatively similar." | 2.68 | Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. ( Carrupt, PA; Cheymol, G; Levron, JC; Poirier, JM; Snoeck, E; Testa, B; Weissenburger, J, 1997) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| " In obese subjects the pharmacokinetic data calculated for sotalol (total clearance (CL), volume of distribution (V beta), half-life of elimination (t1/2), were comparable with those measured in the controls." | 1.28 | [Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects]. ( Cheymol, G, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Cheymol, G | 3 |
| Poirier, JM | 2 |
| Carrupt, PA | 1 |
| Testa, B | 1 |
| Weissenburger, J | 1 |
| Levron, JC | 1 |
| Snoeck, E | 1 |
| Le Jeunne, C | 1 |
| Ertzbischoff, O | 1 |
| Engel, F | 1 |
| Hugues, FC | 1 |
1 trial available for bisoprolol and Obesity
| Article | Year |
|---|---|
Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Adult; Area Under Curve; Benzopyrans; Binding Sites; Bi | 1997 |
3 other studies available for bisoprolol and Obesity
| Article | Year |
|---|---|
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Pharmacokinetics of intravenous bisoprolol in obese and non-obese volunteers.
Topics: Adrenergic beta-Antagonists; Bisoprolol; Cardiovascular System; Female; Humans; Infusions, Intraveno | 1991 |
[Comparison of beta-blocking agents pharmacokinetics in obese and non-obese subjects].
Topics: Adrenergic beta-Antagonists; Adult; Bisoprolol; Female; Humans; Male; Obesity; Propanolamines; Propr | 1990 |